Andrzej Horban

Overview

Best Publications

• Telaprevir for retreatment of HCV infection.

  Stefan Zeuzem;Pietro Andreone;Stanislas Pol;Eric Lawitz

  2104
  Citations

• Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study

  F van Leth;P Phanuphak;K Ruxrungtham;E Baraldi

  981
  Citations

• Maraviroc for Previously Treated Patients with R5 HIV-1 Infection

  Roy M. Gulick;Jacob Lalezari;James Goodrich;Nathan Clumeck

  923
  Citations

• Prevalence of Drug-Resistant HIV-1 Variants in Untreated Individuals in Europe: Implications for Clinical Management

  Annemarie M. J. Wensing;David A. van de Vijver;Gioacchino Angarano;Birgitta Åsjö

  568
  Citations

• Influence of Hepatitis C Virus Infection on HIV-1 Disease Progression and Response to Highly Active Antiretroviral Therapy

  Jiirgen K. Rockstroh;Amanda Mocroft;Vincent Soriano;Cristina Tural

  543
  Citations

• Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease.

  Yun-Fan Liaw;I-Shyan Sheen;Chuan-Mo Lee;Ulus Salih Akarca

  397
  Citations

• Simeprevir With Peginterferon and Ribavirin Leads to High Rates of SVR in Patients With HCV Genotype 1 Who Relapsed After Previous Therapy: A Phase 3 Trial

  Xavier Forns;Eric Lawitz;Stefan Zeuzem;Ed Gane

  362
  Citations

• Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1.

  Frank van Leth;Prahpan Phanuphak;Erik Stroes;Brian Gazzard

  335
  Citations

• Maraviroc versus Efavirenz, Both in Combination with Zidovudine-Lamivudine, for the Treatment of Antiretroviral-Naive Subjects with CCR5-tropic HIV-1 Infection

  David A Cooper;Jayvant Heera;James Goodrich;Margaret Tawadrous

  316
  Citations

• The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus.

  Robert Flisiak;Andrzej Horban;Philippe Gallay;Michael Bobardt

  313
  Citations

• Transmission of Drug-Resistant HIV-1 Is Stabilizing in Europe

  Jurgen Vercauteren;Annemarie M. J. Wensing;David A. M. C. van de Vijver;Jan Albert

  305
  Citations

• The cyclophilin inhibitor Debio 025 combined with PEG IFNα2a significantly reduces viral load in treatment-naive hepatitis C patients.

  Robert Flisiak;Saya V. Feinman;Maciej Jablkowski;Andrzej Horban

  290
  Citations

• A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients.

  Remko Van Leeuwen;Christine Katlama;Robert Murphy;Kathleen Squires

  271
  Citations

• Hepatitis C virus in lymphoid cells of patients coinfected with human immunodeficiency virus type 1: evidence of active replication in monocytes/macrophages and lymphocytes.

  Tomasz Laskus;Marek Radkowski;Andrzej Piasek;Marek Nowicki

  269
  Citations

• The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml.

  Jose R Arribas;Andrzej Horban;Jan Gerstoft;Gerdt Fätkenheuer

  221
  Citations

• Randomized Comparison of Tenofovir Disoproxil Fumarate vs Emtricitabine and Tenofovir Disoproxil Fumarate in Patients With Lamivudine-Resistant Chronic Hepatitis B

  Scott Fung;Peter Kwan;Milotka Fabri;Andrzej Horban

  202
  Citations

• Efficacy and Safety of Atazanavir-Based Highly Active Antiretroviral Therapy in Patients with Virologic Suppression Switched from a Stable, Boosted or Unboosted Protease Inhibitor Treatment Regimen: The SWAN Study (AI424-097) 48-Week Results

  Jose Gatell;Dominique Salmon Ceron;Adriano Lazzarin;Eric Van Wijngaerden

  198
  Citations

• Sequence analysis of in vivo defective interfering-like RNA of influenza A H1N1 pandemic virus.

  Kazima Saira;Xudong Lin;Jay V. DePasse;Rebecca Halpin

  197
  Citations

• Acute hepatitis C in HIV-infected individuals : recommendations from the European AIDS Treatment Network (NEAT) consensus conference The European AIDS Treatment Network (NEAT) Acute Hepatitis C Infection Consensus Panel

  Matthieu Albert;Jose Benito;Sanjay Bhagani;Christoph Boesecke

  196
  Citations

• Updated European recommendations for the clinical use of HIV drug resistance testing

  A. M. Vandamme;A. Sönnerborg;M. Ait-Khaled;J. Albert

  195
  Citations

• Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients.

  Jean-François Delfraissy;Philippe Flandre;Constance Delaugerre;Jade Ghosn

  190
  Citations

• Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe

  L. Marije Hofstra;Nicolas Sauvageot;Jan Albert;Jan Albert;Ivailo Alexiev

  187
  Citations

• Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load.

  Stuart C. Gordon;Zahary Krastev;Andrzej Horban;Jörg Petersen

  153
  Citations

• High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials.

  Patrick Marcellin;Hugo Cheinquer;Manuela Curescu;Geoffrey M. Dusheiko

  133
  Citations

• Time to Virological Failure of 3 Classes of Antiretrovirals after Initiation of Highly Active Antiretroviral Therapy: Results from the EuroSIDA Study Group

  A. Mocroft;B. Ledergerber;J. P. Viard;S. Staszewski

  122
  Citations

• Real‐world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER study

  R. Flisiak;E. Janczewska;M. Wawrzynowicz-Syczewska;J. Jaroszewicz

  115
  Citations